Azenta stock hits 52-week high at 41.84 USD
Azenta Inc. (AZTA) stock reached a 52-week high of $41.84, reflecting a 21.66% increase over the past year and a 52% return in the last six months. This surge follows the company's strong fiscal third-quarter 2026 results, which exceeded Wall Street expectations in both earnings and revenue, driven by demand in sample management and multiomics businesses. Despite trading slightly above its Fair Value according to InvestingPro, management's aggressive share buybacks and a strong cash position indicate positive investor sentiment and growth potential.
Azenta, Inc. Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors who suffered losses. This investigation follows a 12% stock drop on August 24, 2026, after the company announced the resignation of its President and CEO, John P. Marotta. Shareholders are encouraged to contact the firm to join a prospective class action seeking to recover investor losses.
Azenta faces class action over CEO resignation and alleged misleading info, stock dropped 12%.
Rosen Law Firm is investigating potential securities claims against Azenta, Inc. following the resignation of CEO John P. Marotta, which caused a 12% drop in the company's stock price. The firm alleges Azenta may have disseminated materially misleading business information to investors and is preparing a class action lawsuit. Shareholders who purchased Azenta securities are encouraged to contact Rosen Law Firm to participate.
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) following allegations that the company issued materially misleading business information. This investigation comes after Azenta's stock fell 12% on August 24, 2026, when its President and CEO, John P. Marotta, resigned. Investors who purchased Azenta securities are encouraged to contact the firm to inquire about joining a prospective class action to recover losses.
Form 4 Azenta Inc For: 27 September By Investing.com
This article reports on a Form 4 filing for Azenta Inc. on September 27. It is a brief announcement from Investing.com, providing no specific details about the filing itself but includes various market data and other news headlines.
Form 4 Azenta Inc For: 27 September By Investing.com
This article reports on the filing of a Form 4 by Azenta Inc. on September 27. It notes that the company's stock symbol is AZTA and that its price saw a 0.68% increase. The article provides financial market data, including various indices, commodities, and stock performances.
Azenta Faces Multiple Investor Investigations
Azenta Inc. (NASDAQ: AZTA) is currently under investigation by multiple shareholder-rights law firms following a period of financial disappointment, a significant stock drop, and the resignation of its CEO. These investigations, initiated by firms like Rosen Law Firm and Pomerantz LLP, relate to potential securities claims and alleged misleading business information. The scrutiny began after a disappointing fiscal second-quarter report in May and intensified following the August departure of President and CEO John P. Marotta, which caused another dip in stock value.
Azenta faces securities fraud probe after CEO resignation triggers 12% stock drop
Azenta, Inc. is under investigation by Pomerantz LLP for potential securities fraud following the sudden resignation of CEO John Marotta, which caused a 12.09% stock drop. The investigation will examine whether the company and its executives engaged in unlawful activities, and affected investors are encouraged to join a class action lawsuit. This development could significantly impact Azenta's reputation and future stock performance.
Azenta, Inc. (AZTA) Options Chain
This page provides the options chain for Azenta, Inc. (AZTA), detailing call options with various strike prices, last trade dates, bids, asks, and implied volatility. It notes that options data is delayed by 15 minutes and currently shows no put options available. The article also provides current stock information for AZTA, including its real-time price and after-hours trading data.
Tax withholding reduces Azenta (NASDAQ: AZTA) CEO stake
Azenta, Inc.'s Interim CEO, Martin D. Madaus, had 1,456 common shares withheld on September 22, 2026, to cover tax obligations resulting from the vesting of 3,055 restricted stock units. This was a tax withholding transaction, not a market sale, and Madaus directly held 42,602 shares afterward. The reported price per share for the withholding was $34.28.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Azenta, Inc. (AZTA) and its officers/directors. This investigation follows the resignation of CEO John Marotta on August 24, 2026, which led to a 12.09% drop in Azenta's stock price. Investors are encouraged to contact Pomerantz LLP for information on joining the class action.
Azenta formalizes interim CEO pay and retention grants
Azenta has finalized compensation for its interim CEO, Dr. Martin D. Madaus, including a $600,000 annual base salary and $1.2 million in restricted stock units, while also removing him from the nominating and governance committee. Additionally, the company approved retention grants ranging from $500,000 to $1,000,000 in restricted stock units for four senior executives to ensure leadership stability during the transition. TipRanks' AI Analyst, Spark, rates AZTA as Neutral due to mixed financial performance despite a strong balance sheet.
Azenta (AZTA) awards 15,272 stock units to multiomics head
Azenta, Inc. (AZTA) granted 15,272 restricted stock units to William E. Martin III, President Multiomics, on September 14, 2026, as per a Form 4 SEC filing. These units are subject to time-based vesting, with 50% vesting annually starting September 14, 2027. Following this grant, Martin directly holds 33,062 shares of Azenta common stock.
Azenta (NASDAQ: AZTA) Grants 15,272 Shares to Chief Human Resources Officer Pirogova Olga
Azenta (NASDAQ: AZTA) has granted 15,272 shares to its Chief Human Resources Officer, Pirogova Olga, at no cost per share. This transaction, which occurred on September 14, 2026, increased her total holdings to 47,225 shares. The grant represents approximately 32.3% of her total shareholding after the award.
Azenta (AZTA) awards HR chief 15,272 restricted stock units
Azenta, Inc. (AZTA) announced that its Senior Vice President and Chief Human Resources Officer, Olga Pirogova, received a grant of 15,272 restricted stock units (RSUs) on September 14, 2026. These RSUs are subject to time-based vesting, with 50% vesting annually starting September 14, 2027. Following this grant, Pirogova directly holds 47,225 shares of Azenta common stock.
Azenta (AZTA) grants 4,586 stock units to accounting VP
Azenta, Inc. (AZTA) reported via a Form 4 filing that Erik J. Bello, Vice President and Chief Accounting Officer, received a grant of 4,586 restricted stock units (RSUs) on September 15, 2026. These RSUs were granted under the company’s Equity Incentive Plan with no cash payment and are subject to time-based vesting. The vesting will occur in three equal annual installments starting on September 15, 2027.
Azenta (AZTA) interim CEO gets new year-long stock grant
Azenta, Inc. (AZTA) announced that interim CEO Martin D. Madaus received a grant of 36,653 restricted stock units (RSUs) on September 14, 2026, under the company’s Equity Incentive Plan. These RSUs, for which no amount was paid, will vest 1/12 per month over twelve months and will settle in common stock, increasing his direct holdings to 44,058 shares. This grant aims to align the CEO's incentives with shareholder value, and it was not made under a Rule 10b5-1 trading plan.
Form 8K Azenta Inc For: 17 September By Investing.com
This article reports on the filing of a Form 8K by Azenta Inc. on September 17, 2026. The brief announcement provides no further details about the content of the filing but includes a link to view comments and stock performance data for AZTA.
Azenta (NASDAQ: AZTA) Grants 15,272 Shares to Multiomics President Martin William E. III
Azenta (NASDAQ: AZTA) recently granted 15,272 shares to Martin William E. III, its President of Multiomics, at no cost. This award, representing approximately 46.2% of his total holdings, increased his stake to 33,062 shares. The transaction was designated with code A, indicating an acquisition from the company.
Azenta CFO Lin Lawrence Receives 30,544 Shares at No Cost, Representing 27.7% of His Holdings
Azenta, Inc. (NASDAQ:AZTA) awarded its CFO, Lin Lawrence Y., 30,544 shares at no cost, which represents approximately 27.7% of his total holdings in the company. The transaction was recorded on September 14, 2026, and post-transaction, Lin Lawrence Y. held 110,199 shares of Azenta. This significant award increases his total shareholding and reflects his continued ownership in the company.
Azenta Secures Full $35M Vendor Loan Repayment from B Medical Buyer Ahead of Schedule
Azenta, Inc. announced that Thelema S.e0 r.l. has fully repaid a $35 million vendor loan ahead of schedule, increasing the total cash proceeds from the sale of B Medical Systems S.e0 r.l. to $63 million. The early repayment, including accrued interest, was completed on September 3, 2026, lifting the collateral pledge on B Medical's equity. This transaction finalizes the sale and provides Azenta with the full purchase price in cash.
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems
Azenta, Inc. announced the full repayment of a $35 million secured vendor loan, along with accrued interest, related to the sale of B Medical Systems S.à r.l. to Thelema S.à r.l. This repayment completes the divestiture, meaning Azenta has now received the entire $63 million purchase price in cash. The company highlighted that this aligns with its disciplined approach to capital allocation and eliminates the credit exposure from the transaction.
How (AZTA) Movements Inform Risk Allocation Models
This article analyzes Azenta Inc. (NASDAQ: AZTA) using AI models to inform risk allocation. It highlights weak near-term sentiment despite mid-term strength within a broader long-term weak bias, noting no clear price positioning signal or resistance levels above the current price. The analysis provides three institutional trading strategies tailored to different risk profiles: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, along with multi-timeframe signal analysis.
Azenta (AZTA) Earnings Date and Reports 2026
Azenta (AZTA) recently reported its Q3 2026 earnings, surpassing analyst expectations with an EPS of $0.16 and revenue of $161.18 million. The company's next earnings report, for Q4, is estimated to be on November 20, 2026, before market opens. The article provides historical earnings and revenue data, along with resources for investors to stay updated on Azenta's financial performance.
Stocks making big moves yesterday: Funko, Hims & Hers Health, Azenta, Strategy, and RUM Group
This article details the stock movements of several companies yesterday. Funko rose after Seaport Research initiated Buy coverage, while Hims & Hers Health fell due to Visa's monitoring program over credit card disputes. Azenta also declined following the resignation of its CEO, and Strategy and RUM Group both saw increases due to new liquidity and a major contract, respectively.
Azenta tumbles 12% after CEO transition (AZTA:NASDAQ)
Shares of Azenta (AZTA) fell nearly 12% after the company announced the resignation of its President, CEO, and director, John Marotta, who will be replaced by board member Martin Madaus. Despite the company reaffirming its revenue guidance, investors showed concern over the unexpected leadership change and the associated costs, especially since the fiscal 2026 guidance trails management's long-term growth model.
Azenta CEO John Marotta Steps Down; Dr. Martin Madaus Named Interim CEO
John P. Marotta has resigned as President and CEO of Azenta, Inc. (NASDAQ:AZTA) effective August 22, 2026. The Board of Directors has appointed Dr. Martin D. Madaus as Interim President and CEO. Dr. Madaus, a current Board member, will also assume principal executive officer duties for SEC filings, and his compensation for this interim role is currently under review.
Azenta Names Martin Madaus Interim CEO, Reaffirms Revenue Guidance
Azenta Inc. has appointed Dr. Martin Madaus as interim President and CEO following the resignation of John Marotta, while reaffirming its Q4 fiscal 2026 revenue guidance. Madaus, a board member with extensive industry experience, will lead the company through this transition, focusing on profitability improvement and capital allocation. The company also clarified that adjusted EBITDA would be affected by a one-time $3 million consulting expense but otherwise reiterated its financial outlook.
ETFs Investing in Azenta, Inc. Stocks
This article provides a list of ETFs that hold stocks of Azenta, Inc., sorted by market value. It details various ETFs, including their market value, weight of Azenta, Inc. stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify funds that offer diversified exposure to Azenta, Inc. with potentially lower risk.
Azenta (AZTA) Is Up 11.5% After Returning To Profit And Raising Revenue Outlook - Has The Bull Case Changed?
Azenta (AZTA) recently reported a return to profitability in Q3 2026, with net income of US$2.46 million and revenue of US$161.18 million, alongside a US$50 million share repurchase. The company also raised its full-year revenue guidance to US$613-US$618 million, signaling increased confidence in its operations. While these developments support the bull case for Azenta's long-term profitability in sample management and multiomics, the article cautions that ongoing pressures in certain services and elevated R&D spending could still impact margins and free cash flow.
Azenta (AZTA) Is Up 11.5% After Returning To Profit And Raising Revenue Outlook - Has The Bull Case Changed?
Azenta (AZTA) reported a strong third quarter in 2026, returning to profitability with US$2.46 million in net income and US$161.18 million in revenue, while also raising its full-year revenue guidance to US$613-US$618 million. The company completed a US$50 million share repurchase, which, combined with the return to positive earnings, suggests a more confident outlook for its operations and cash generation. While these updates are positive, the article notes that ongoing softness in certain business lines and high R&D spending could still impact future margins and free cash flow.
Weekly Recap: Azenta, Inc. Q3 revenue gain and analyst target raises
Azenta, Inc. (NASDAQ:AZTA) reported a strong Q3 with revenue up 12% year-over-year to $161.2M, driven by organic growth in Sample Management and Multiomics. The company announced a new buyback program, maintaining strong liquidity, and analysts subsequently raised price targets to $35 and $37 with buy/outperform ratings.
ETFs Investing in Azenta, Inc. Stocks
This article provides a list of ETFs that hold Azenta, Inc. stocks, detailing each fund's market value, weight of Azenta in its portfolio, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to make investing in Azenta through ETFs more accessible by highlighting diversified options with potentially lower risk.
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Azenta, Inc. (AZTA) on behalf of investors who lost money. The investigation follows Azenta's Q2 2026 financial results, which missed consensus estimates and led to a significant stock price drop after the company reduced its 2026 outlook and reported a goodwill impairment. Shareholders are urged to contact the firm to inquire about potentially pursuing claims.
Azenta, Inc. $AZTA Shares Sold by Bank of New York Mellon Corp
Bank of New York Mellon Corp decreased its stake in Azenta, Inc. (NASDAQ:AZTA) by 26.1% in the first quarter, selling 88,074 shares and retaining 249,272 shares valued at approximately $5.27 million. Despite this, other institutional investors increased their holdings, and Azenta reported stronger-than-expected quarterly earnings and revenue, leading to a 5.4% increase in its stock price at market open. Analysts currently have a "Hold" rating on the stock with an average price target of $41.20, and the company raised its fiscal 2026 revenue outlook.
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues
Glancy Prongay Wolke & Rotter LLP is continuing its investigation into Azenta, Inc. (NASDAQ: AZTA) for potential violations of federal securities laws. This follows a significant drop in Azenta's stock price after the company reported disappointing Q2 2026 financial results, including missing EPS and revenue estimates, recording a $149 million goodwill impairment, and reducing its 2026 outlook. Shareholders who incurred losses are encouraged to contact the law firm to learn about potentially pursuing claims.
Azenta, Inc. $AZTA Stake Cut by Quantinno Capital Management LP
Quantinno Capital Management LP significantly reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 63.3% in the first quarter, selling over 391,000 shares and retaining 226,690 shares valued at approximately $4.79 million. Despite this, Azenta recently surpassed quarterly earnings expectations, reporting an adjusted EPS of $0.16 against a $0.11 consensus and revenue of $161.18 million. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $41.20, although Needham raised its target to $37.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Azenta, Inc. (AZTA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors. This follows Azenta's Q2 2026 financial results, which missed consensus estimates for EPS and revenue, reported a $149 million goodwill impairment, and led to a reduced 2026 outlook. The firm encourages affected investors to contact them to assist with the investigation.
Arrowstreet Capital Limited Partnership Buys New Position in Azenta, Inc. $AZTA
Arrowstreet Capital Limited Partnership has acquired a new position in Azenta, Inc. (NASDAQ:AZTA), purchasing 71,410 shares valued at approximately $1.51 million, representing about 0.15% of the company. This comes as Azenta reported strong quarterly earnings, exceeding analyst estimates for both EPS and revenue, though it still maintains a negative net margin. Institutional investors hold a significant 99.08% stake in Azenta, and analyst sentiment is mixed but leaning positive, with Needham raising its price target to $37.
Azenta, Inc. 3Q 2026: Revenue $161.18M, EPS $0.05— 10-Q Summary
Azenta, Inc. reported strong third-quarter 2026 results, with revenue increasing 12% year-over-year to $161.18 million and diluted EPS reaching $0.05, a significant improvement from a loss in the prior year. The company returned to a net income of $2.46 million, driven by growth in its SMS and Multiomics segments and the acquisition of the UK Biocentre. Azenta also divested B Medical Systems to sharpen its strategic focus.
Azenta, Inc. Stock 12‑Month Price Target Raised to $33.8, Implies 12% Upside
Azenta, Inc.'s stock price target has been increased from $27.8 to $33.8 by five analysts, implying a 12% potential upside based on its August 4th closing price. The consensus rating for the stock remains a "Buy" from six analysts. Investors can find more detailed price target data and analyst recommendations on the Forecasts tab and News Flow sections of TradingView.
Azenta Q3 2026 EPS Tops Expectations, Revenue Up 12%
Azenta, Inc. reported strong Q3 2026 results, with Non-GAAP Diluted EPS of $0.16, significantly exceeding Wall Street's estimate of $0.12. The company's revenue rose 12.0% year-over-year to $161.2M, primarily driven by impressive organic growth of 9.0% and strong performance in its Sample Management Solutions segment. Despite the positive financial performance, Azenta's shares traded largely unchanged, possibly due to broader market concerns or investors awaiting clearer forward guidance.
Azenta, Inc. (AZTA) SVP acquires 335 shares via 2017 stock purchase plan
Ephraim Starr, SVP, General Counsel & Secretary of Azenta, Inc. (AZTA), purchased 335 shares of common stock on July 31, 2026, at $24.1676 per share through the company's 2017 Employee Stock Purchase Plan. This transaction, which was exempt from Section 16(b), increased his direct holdings to 68,728 shares. The filing was accepted by the SEC on August 4, 2026, and provides details of the insider trading activity.
Earnings Flash (AZTA) Azenta, Inc. Posts Q3 Adjusted EPS $0.16 per Share
Azenta, Inc. (AZTA) announced its Q3 adjusted EPS of $0.16 per share, surpassing FactSet's estimate of $0.11. The company also reported Q3 revenue of $161.2 million, exceeding FactSet's estimate of $149.3 million. This financial update indicates a stronger performance than anticipated by analysts for the quarter ended June 30, 2026.
Azenta reports Q3 fiscal 2026: Revenue $161M, Adjusted EBITDA $18.5M, Non-GAAP EPS $0.16
Azenta (AZTA) reported its fiscal Q3 2026 results with revenue of $161.2 million and non-GAAP diluted EPS of $0.16. The company achieved an adjusted EBITDA of $18.5 million, representing an 11.4% margin, and noted 9% organic revenue growth year over year. Azenta also reiterated its fiscal 2026 adjusted EBITDA guidance of $59–62 million.
Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
Azenta, Inc. reported its third-quarter financial results for fiscal year 2026, exceeding expectations with continued strength in recurring revenue and a modest improvement in Multiomics in North America. The company's revenue from continuing operations was $161 million, an increase of 12% year-over-year, and it issued updated guidance for both the fourth quarter and full fiscal year 2026. This report also included details on the sale of its B Medical Systems business, which was completed on July 1, 2026.
Azenta earnings on deck: Can life sciences firm return to profit?
Azenta Inc. is scheduled to report its fiscal third-quarter earnings, with analysts expecting a return to profitability at $0.10 per share on $149.29 million in revenue, a significant improvement from the previous quarter's loss. Investors will be closely watching for sustained profitability, North American demand trends, and improvements in margins following management's acknowledgment of prior execution gaps and a cautious market. The company has taken steps to streamline its portfolio and introduce new products, and upcoming results will be crucial for validating its recovery efforts.
Earnings Flash (AZTA) Azenta, Inc. Reports Q3 Revenue $161.2M, vs. FactSet Est of $149.3M
Azenta, Inc. (AZTA) reported its Q3 revenue at $161.2 million, surpassing FactSet's estimate of $149.3 million. This financial news highlights a stronger-than-anticipated performance for the biotechnology and medical research company in its third fiscal quarter. The report also mentions other recent financial updates for Azenta, including its Q3 adjusted EPS and revised earnings guidance.
Earnings Flash (AZTA) Azenta, Inc. Posts Q3 Adjusted EPS $0.16 per Share, Vs. FactSet Est of $0.11
Azenta, Inc. (AZTA) announced its Q3 adjusted EPS of $0.16 per share, surpassing the FactSet estimate of $0.11 per share. This indicates a stronger financial performance than anticipated by analysts.
Azenta (AZTA) Reports Q2: Everything You Need To Know Ahead Of Earnings
Azenta (AZTA) is set to report its Q2 earnings this Tuesday. The company missed revenue and EPS expectations last quarter, but analysts expect a 3.7% year-on-year revenue growth for the upcoming quarter, reversing a previous decline. Investors are keen to see if Azenta, currently trading near its average analyst price target, can deliver a positive surprise.
